What is a soft tissue sarcoma?

Soft tissue sarcoma is a form of cancer that develops in the connective tissues—blood vessels, cartilage, fat, ligaments, lymph vessels, muscles, nerves, and tendons. These tumors most often occur in the arms and legs (60 percent of cases), but can also be found in the retroperitoneum, or back half of the belly (20 percent of cases), pelvis, spine, neck, head, chest, buttocks, or uterus.

Soft tissue sarcomas are rare, but occur more often than bone sarcomas. They are also more likely to metastasize (spread) before being diagnosed and to return after treatment. Some soft tissue sarcomas are more aggressive than others.

Research shows that people with soft tissue sarcoma often have better outcomes and quality of life when they receive care from a team experienced in treating these rare cancers. The Sarcoma Program at Penn Medicine’s Abramson Cancer Center includes nationally recognized experts who work closely with specialists across many fields, including surgeons who focus on specific areas of the body.

How soft tissue sarcoma may appear

There are more than 50 subtypes of soft tissue sarcomas:

Among the tumors listed, UPS is the most common, followed by liposarcoma, leiomyosarcoma, and GIST.

Soft tissue sarcoma symptoms

Many soft tissue sarcomas don’t cause symptoms. Unlike other cancers, they may push body parts aside rather than grow into them. Still, the tumors may offer some signs such as a firm mass. These signs depend on where in the body the sarcoma develops.

Soft tissue sarcoma causes and risk factors

Doctors know that a particular soft tissue sarcoma called Kaposi sarcoma is caused by a virus called human herpesvirus 8 (HHV8). However, they don’t usually know what causes other soft tissue sarcomas, and you can’t typically reduce your risk of developing one.

Sometimes, radiation therapy can lead to the later development of soft tissue sarcoma, an uncommon side effect that occurs less frequently with newer types of radiation. Another radiation side effect, swelling called lymphedema, can also raise soft tissue sarcoma risk. Past workplace exposure to the chemicals chloride monomer, dioxin, or Agent Orange may also have ties to soft tissue sarcomas.

Some people inherit genetic variants (changes) tied to rare syndromes. These syndromes cause various symptoms and diseases and can raise the risk for some cancers, including sarcomas. The genetic syndromes tied to higher risk for soft tissue tumors include:

  • Carney-Stratakis syndrome: GIST
  • Familial GIST: GIST
  • Familial adenomatous polyposis (FAP): Desmoid tumor (benign)
  • Hereditary leiomyomatosis and renal cell cancer (HLRCC): Leiomyosarcoma in the uterus
  • Hereditary retinoblastoma: Fibrosarcoma, liposarcoma, leiomyosarcoma
  • Li–Fraumeni syndrome (LFS): Rhabdomyosarcoma and, much less frequently, fibrosarcoma, leiomyosarcoma, orbital (near the eyes) liposarcoma, and UPS
  • Neurofibromatosis type 1 (NF1): GIST, malignant peripheral nerve sheath tumor, rhabdomyosarcoma, and UPS
  • Tuberous sclerosis complex: Various benign soft tissue tumors

A number of additional rare, genetic syndromes can also raise the risk for a type of rhabdomyosarcoma called embryonal rhabdomyosarcoma.

If one of these syndromes runs in your family, specialists at Penn Medicine can provide genetic testing and counseling.

Finding and diagnosing soft tissue sarcoma

Taking scans is the first step in evaluating soft tissue sarcoma. Sometimes, that imaging clearly rules out sarcoma. If we need more information, we may recommend a biopsy to take a tissue sample from the lump or bump.

How we treat soft tissue sarcoma

The primary goal of soft tissue sarcoma treatment is to remove the tumor. Surgeons specialized in various areas of the body work to remove soft tissue sarcomas in one piece with an appropriate border of normal tissue.

Orthopaedic oncologists lead treatment for the arms, legs, and pelvis, while surgical oncologists treat tumors in the retroperitoneum. Neurosurgeons work on spinal tumors and gynecologic oncologists on uterine tumors. Head and neck surgeons may participate in tumor removals involving the head and neck as well.

To reduce the chances of soft tissue sarcoma returning after surgery, we treat some tumors with radiation therapy first. This treatment is most common for tumors in the arms and legs.

For soft tissue sarcoma that spreads, we may recommend chemotherapy, targeted therapy, or immunotherapy. Our team also participates in clinical trials to find more effective solutions for advanced disease.

Experience matters in sarcoma care

Because soft tissue sarcomas are uncommon, finding experienced specialists is important. At Penn Medicine’s Abramson Cancer Center, we see more than 500 new sarcoma cases and perform more than 100 specialized surgeries each year. Treating a high volume of sarcomas gives our team extensive experience caring for complex and rare tumors.

We offer:

  • Specialized expertise: Our dedicated sarcoma team includes surgeons, oncologists, radiologists, pathologists, and others who work closely together to diagnose and treat soft tissue sarcomas.
  • Team-based planning: Experts from different specialties review every case together at tumor board meetings to recommend the most effective treatment approach.
  • Access to clinical trials: As a member of the Sarcoma Alliance for Research through Collaboration (SARC), we offer access to sarcoma clinical trials and emerging treatments.
  • Care across age groups: We partner with the sarcoma program at Children’s Hospital of Philadelphia (CHOP) when appropriate and help younger people transition smoothly to adult care when needed.
National Cancer Institute Designated Comprehensive Cancer Center badge on top of shot of hospital

Rated “exceptional” by The National Cancer Institute

Penn Medicine’s Abramson Cancer Center is a world leader in cancer research, patient care, and education. Our status as a national leader in cancer care is reflected in our continuous designation as a Comprehensive Cancer Center by the National Cancer Institute (NCI) since 1973, one of 7 such centers in the United States. The ACC is also a member of the National Comprehensive Cancer Network, one of a select few cancer centers in the U.S., that are working to promote equitable access to high-quality, advanced cancer care.

Related specialties

Schedule an appointment

We can help you schedule an appointment or you can search our directory of specialists.